Back to search results

Precision Radiotherapy for Brain Cancer Using Molecular MRI

This study is looking at a new way to plan radiation treatment for brain cancer, specifically glioblastoma or grade 4 astrocytoma. Researchers are testing if a special type of MRI, called amide proton transfer (APT) imaging, can help identify the most aggressive parts of the tumor. You would receive either this new APT-guided radiation (Amide proton transfer radiotherapy) or standard radiation therapy. The main goal is to see how much the APT signal changes, which helps understand how effective the new APT-guided radiation is. To join, you need to be over 18, have a good performance status (KPS at least 60), and have normal organ and blood cell counts. The study plans to enroll 20 people.

Study design
This is an interventional study comparing a new radiation treatment with standard radiation treatment. It plans to enroll 20 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your APTw signal will be measured from the start of the study until 4 weeks after your radiation treatment is completed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07512154

Precision Radiotherapy Enabled by Molecular MRI

Recruiting
NAAges 18+InterventionalTreatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
~20 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:Amide proton transfer radiotherapyStandard radiotherapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in APTw signal (Efficacy of APT-RT)
Measured over From baseline to 4 weeks post completion of RT.

Conditions

Brain Cancer

Explore related trials

Glioblastoma

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Kristin Redmond · PRINCIPAL_INVESTIGATOR · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Who to contact

Kristin Redmond
[email protected]
410-614-1642
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologic confirmation of glioblastoma or grade 4 astrocytoma
Age \>18
KPS at least 60
Patients must have normal organ and marrow function as defined below:
leukocytes \>3,000/mcL
absolute neutrophil count \>1,500/mcL
platelets \>100,000/mcL
total bilirubin within normal institutional limits
AST(SGOT)/ALT(SGPT) \<2.5
institutional upper limit of normal
creatinine within normal institutional limits OR creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
Patients of child-bearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion

Patients who are unable to receive MRIs will be excluded from the study.
Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment.
Patients may not have previously been treated with an overlapping course of radiotherapy to the brain.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant and/or breastfeeding women are excluded. Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 12 weeks after the study are excluded. Male subjects must also agree to use effective contraception for the same period as above.

What this trial measures

  • Change in APTw signal (Efficacy of APT-RT)From baseline to 4 weeks post completion of RT.

    A reduction in APTw signal following treatment suggests a positive response to therapy (active tumor APTw = 3-4% vs. necrosis/no tumor APTw 1-2%). A 1% greater reduction in mean APTw signal change within the Gd-enhancing tumor region from baseline (pre-RT) to post-RT in the APT-RT arm, compared to the control arm.